Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.

ABSTRACT:

Significance

Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2- breast cancer, which represents ∼70% of all cases.

SUBMITTER: Alam R 

PROVIDER: S-EPMC11964846 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature